Advanced BioHealing, which was purchased by Shire in 2011, has now been renamed Shire Regenerative Medicine.
The clinical research specialist aims to develop and deliver solutions to boost the body's natural healing process, with DERMAGRAFT existing as the company's leading regenerative medicine product.
Kevin Rakin, president of Shire Regenerative Medicine, said: "As the partner of choice for development-stage companies, we aspire to address society's unmet medical needs by harnessing the power of regenerative medicine."
Mr Rakin went on to say that the rebranding is an "exciting milestone" that illustrates its commitment to offering regenerative medicine solutions.
The company's new name is active now, with the full rebranding set to be completed by the end of 2012.
Recently, Shire's velaglucerase alfa for injection (VPRIV) therapy was found to boost the health of patients with Goucher-related bone disease.
VPRIV improves the condition by triggering a rise in bone mineral density, which can then be utilised to analyse how the illness is affecting patients' bones.